S&P 500   4,583.41 (+0.70%)
DOW   35,648.50 (+0.44%)
QQQ   382.61 (+0.69%)
AAPL   152.34 (+2.34%)
MSFT   322.66 (-0.16%)
FB   315.05 (+0.91%)
GOOGL   2,922.19 (-0.07%)
TSLA   1,071.05 (+3.20%)
AMZN   3,466.99 (+2.20%)
NVDA   247.03 (+1.03%)
BABA   169.91 (+0.40%)
NIO   40.53 (+3.10%)
CGC   12.83 (+0.39%)
GE   104.02 (+0.16%)
AMD   120.92 (-1.11%)
MU   69.45 (+1.77%)
T   25.58 (+2.08%)
F   16.94 (+9.22%)
ACB   6.85 (+0.15%)
DIS   169.98 (+0.25%)
PFE   43.13 (+0.37%)
BA   206.73 (+0.06%)
AMC   35.07 (+0.89%)
S&P 500   4,583.41 (+0.70%)
DOW   35,648.50 (+0.44%)
QQQ   382.61 (+0.69%)
AAPL   152.34 (+2.34%)
MSFT   322.66 (-0.16%)
FB   315.05 (+0.91%)
GOOGL   2,922.19 (-0.07%)
TSLA   1,071.05 (+3.20%)
AMZN   3,466.99 (+2.20%)
NVDA   247.03 (+1.03%)
BABA   169.91 (+0.40%)
NIO   40.53 (+3.10%)
CGC   12.83 (+0.39%)
GE   104.02 (+0.16%)
AMD   120.92 (-1.11%)
MU   69.45 (+1.77%)
T   25.58 (+2.08%)
F   16.94 (+9.22%)
ACB   6.85 (+0.15%)
DIS   169.98 (+0.25%)
PFE   43.13 (+0.37%)
BA   206.73 (+0.06%)
AMC   35.07 (+0.89%)
S&P 500   4,583.41 (+0.70%)
DOW   35,648.50 (+0.44%)
QQQ   382.61 (+0.69%)
AAPL   152.34 (+2.34%)
MSFT   322.66 (-0.16%)
FB   315.05 (+0.91%)
GOOGL   2,922.19 (-0.07%)
TSLA   1,071.05 (+3.20%)
AMZN   3,466.99 (+2.20%)
NVDA   247.03 (+1.03%)
BABA   169.91 (+0.40%)
NIO   40.53 (+3.10%)
CGC   12.83 (+0.39%)
GE   104.02 (+0.16%)
AMD   120.92 (-1.11%)
MU   69.45 (+1.77%)
T   25.58 (+2.08%)
F   16.94 (+9.22%)
ACB   6.85 (+0.15%)
DIS   169.98 (+0.25%)
PFE   43.13 (+0.37%)
BA   206.73 (+0.06%)
AMC   35.07 (+0.89%)
S&P 500   4,583.41 (+0.70%)
DOW   35,648.50 (+0.44%)
QQQ   382.61 (+0.69%)
AAPL   152.34 (+2.34%)
MSFT   322.66 (-0.16%)
FB   315.05 (+0.91%)
GOOGL   2,922.19 (-0.07%)
TSLA   1,071.05 (+3.20%)
AMZN   3,466.99 (+2.20%)
NVDA   247.03 (+1.03%)
BABA   169.91 (+0.40%)
NIO   40.53 (+3.10%)
CGC   12.83 (+0.39%)
GE   104.02 (+0.16%)
AMD   120.92 (-1.11%)
MU   69.45 (+1.77%)
T   25.58 (+2.08%)
F   16.94 (+9.22%)
ACB   6.85 (+0.15%)
DIS   169.98 (+0.25%)
PFE   43.13 (+0.37%)
BA   206.73 (+0.06%)
AMC   35.07 (+0.89%)
NASDAQ:CERS

Cerus Stock Forecast, Price & News

$6.42
+0.16 (+2.56 %)
(As of 10/28/2021 01:03 PM ET)
Add
Compare
Today's Range
$6.27
$6.44
50-Day Range
$5.69
$6.68
52-Week Range
$4.67
$8.87
Volume
22,156 shs
Average Volume
1.69 million shs
Market Capitalization
$1.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.22
30 days | 90 days | 365 days | Advanced Chart
Receive CERS News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter.


Cerus logo

About Cerus

Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:CERS
CUSIP
15708510
Employees
266
Year Founded
1991

Sales & Book Value

Annual Sales
$91.92 million
Book Value
$0.62 per share

Profitability

Net Income
$-59.86 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$1.10 billion
Next Earnings Date
11/2/2021 (Confirmed)
Fiscal Year End
N/A
Optionable
Optionable

Social Links


MarketRank

Overall MarketRank

1.61 out of 5 stars

Medical Sector

978th out of 1,372 stocks

Surgical & Medical Instruments Industry

98th out of 125 stocks

Analyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Cerus (NASDAQ:CERS) Frequently Asked Questions

What stocks does MarketBeat like better than Cerus?

Wall Street analysts have given Cerus a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cerus wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Cerus' next earnings date?

Cerus is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for Cerus
.

How can I listen to Cerus' earnings call?

Cerus will be holding an earnings conference call on Tuesday, November 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "3970817".

How were Cerus' earnings last quarter?

Cerus Co. (NASDAQ:CERS) announced its earnings results on Tuesday, August, 3rd. The biotechnology company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01. The biotechnology company earned $31.48 million during the quarter, compared to analyst estimates of $26.10 million. Cerus had a negative net margin of 57.50% and a negative trailing twelve-month return on equity of 62.92%.
View Cerus' earnings history
.

How has Cerus' stock been impacted by COVID-19?

Cerus' stock was trading at $4.76 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CERS stock has increased by 34.0% and is now trading at $6.38.
View which stocks have been most impacted by COVID-19
.

What guidance has Cerus issued on next quarter's earnings?

Cerus updated its FY 2021 earnings guidance on Tuesday, August, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $118 million-$122 million, compared to the consensus revenue estimate of $134.80 million.

Who are Cerus' key executives?

Cerus' management team includes the following people:

What is William M. (Obi) Greenman's approval rating as Cerus' CEO?

15 employees have rated Cerus CEO William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among Cerus' employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cerus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA).

What is Cerus' stock symbol?

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Who are Cerus' major shareholders?

Cerus' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (7.16%), First Midwest Bank Trust Division (0.38%), Stephens Inc. AR (0.38%), Roubaix Capital LLC (0.34%), Exchange Traded Concepts LLC (0.19%) and Bouvel Investment Partners LLC (0.12%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson, Timothy L Moore, Vivek K Jayaraman, Vivek K Jayaraman and William Mariner Greenman.
View institutional ownership trends for Cerus
.

Which institutional investors are selling Cerus stock?

CERS stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., First Midwest Bank Trust Division, Exchange Traded Concepts LLC, and Taylor Cottrill Erickson & Associates Inc.. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Timothy B Anderson, Vivek K Jayaraman, and William Mariner Greenman.
View insider buying and selling activity for Cerus
or view top insider-selling stocks.

Which institutional investors are buying Cerus stock?

CERS stock was acquired by a variety of institutional investors in the last quarter, including Bouvel Investment Partners LLC, Roubaix Capital LLC, and Stephens Inc. AR.
View insider buying and selling activity for Cerus
or or view top insider-buying stocks.

How do I buy shares of Cerus?

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cerus' stock price today?

One share of CERS stock can currently be purchased for approximately $6.38.

How much money does Cerus make?

Cerus has a market capitalization of $1.09 billion and generates $91.92 million in revenue each year. The biotechnology company earns $-59.86 million in net income (profit) each year or ($0.37) on an earnings per share basis.

How many employees does Cerus have?

Cerus employs 266 workers across the globe.

When was Cerus founded?

Cerus was founded in 1991.

What is Cerus' official website?

The official website for Cerus is www.cerus.com.

Where are Cerus' headquarters?

How can I contact Cerus?

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company can be reached via phone at (925) 288-6000 or via email at [email protected].


This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.